MUMSS
CRSP icon

Mitsubishi UFJ Morgan Stanley Securities’s CRISPR Therapeutics CRSP Stock Holding History

Mitsubishi UFJ Morgan Stanley Securities’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-610
Closed -$93K – 19
2020
Q4 		$93K Buy
+610
New +$72.1K 0.08% 24

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Mitsubishi UFJ Morgan Stanley Securities's CRSP Position: Q1 2021 in Review

Mitsubishi UFJ Morgan Stanley Securities sold out of CRISPR Therapeutics (CRSP) in Q1 2021, closing a stake of 610 shares — an estimated $93K sold.

Mitsubishi UFJ Morgan Stanley Securities first reported a position in CRSP in Q4 2020 and held it in 1 quarter. The position peaked at $93K in Q4 2020. 443 funds tracked by Wall St. Rank hold CRSP as of Q1 2021.

  • Mitsubishi UFJ Morgan Stanley Securities reported no remaining CRISPR Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Mitsubishi UFJ Morgan Stanley Securities sold 610 CRISPR Therapeutics shares in Q1 2021, an estimated $93K.
  • Mitsubishi UFJ Morgan Stanley Securities first reported a position in CRISPR Therapeutics in Q4 2020 and held it in 1 quarter.
  • Mitsubishi UFJ Morgan Stanley Securities's CRISPR Therapeutics position peaked at $93K in Q4 2020.
  • 443 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2021.

Based on Mitsubishi UFJ Morgan Stanley Securities's 13F filing for Q1 2021, filed 14 May 2021.